Author: Oxford Gene Technology
Download this free white paper for detailed insight into the advantages of autoantibodies as biomarkers, including a review of the current technology and best practices for identification of sensitive and specific autoantibody biomarkers.
Author: STEMCELL Technologies
Find out why using CFC assays to obtain information on the hematological effects of a new drug is a quick and cost-effective way to make more informed decisions concerning progression through the drug pipeline.
Author: Integrated DNA Technologies
Dr John Rossi is Chair and Professor of the Department of Molecular and Cellular Biology at the Beckman Research Institute of City of Hope (Duarte, CA). His research focuses on the biology and applications of eukaryotic small RNAs and, in particular, their therapeutic use in HIV/AIDS and cancer. One of IDT’s Scientific Writers recently had the opportunity to talk with Dr Rossi about the field of RNAi as therapeutics and his own path in science.
Author: illumina
RNA-Seq is a powerful sequencing-based method that enables researchers to discover, profile, and quantify RNA transcripts across the entire transcriptome. Because the method does not require probes or primers, the generated data are completely unbiased, allowing for hypothesis-free experimental design. The ability to perform this type of analysis provides researchers a powerful tool for transcript discovery applications that are not possible using traditional microarray-based methods1. Beyond gene expression analysis, RNA-Seq can identify novel transcripts, novel isoforms, alternative splice sites, allele-specific expression, and rare transcripts in a single experiment.
Author: Merck Millipore
Profiling of putative lead compounds against a representative panel of important enzymes, receptors, ion channels and transporters is an excellent way to establish a preliminary view of potential issues that might later hamper development. An early idea of which off-target activities must be minimized can save valuable time and money during the preclinical lead optimization phase if pivotal questions are asked beyond the usual profiling at hERG. The best data for critical evaluation of activity at GPCRs and ion channels is obtained using functional assays, since binding assays cannot detect all interactions and do not provide information on whether the interaction is that of an agonist, antagonist, or allosteric modulator. This overview discusses the benefits of in vitro assays, specific decision points where profiling can be of immediate benefit, and highlights relevant profiling services offered by Merck Millipore.
This free to view PAT supplement is sponsored by Sartorius, Extrel, ABB, Bruker Optics and FOSS NIRSystems:
ABB Analytical Measurements | Almac | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Daltonik GmbH | CAMO Software AS | CI Precision | Cisbio Bioassays | Colder Products Company | Expo Technologies, LLC. | Freeman Technology | GE Analytical Instruments | HACH LANGE GMBH | HORIBA Scientific | Natoli Engineering Company, Inc. | Peter Huber Kältemaschinenbau GmbH | Randox Pharma Services | Rapid Micro Biosystems | Synbiosis | Syngene | Watson-Marlow Pumps Group |
© Russell Publishing Limited, 2010-2012. All rights reserved | Website design and development by e-Motive Media | Terms & conditions of use | Privacy policy
Login to access exclusive content